Secondary prevention for coronary artery disease: are we following the guidelines?

Hdl Handle:
http://hdl.handle.net/10147/207976
Title:
Secondary prevention for coronary artery disease: are we following the guidelines?
Authors:
Syed, I A A; Riaz, A; Ryan, A; Reilly, M O
Affiliation:
Waterford Regional Hospital, Waterford, Ireland. asimsyed01@hotmail.com
Citation:
Ir J Med Sci. 2010 Dec;179(4):535-7. Epub 2010 Jul 31.
Journal:
Irish journal of medical science
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207976
DOI:
10.1007/s11845-010-0527-x
PubMed ID:
20676796
Abstract:
BACKGROUND: Secondary prevention pharmacotherapy in post-myocardial infarction (MI) patients reduces the risk of subsequent coronary events and overall mortality. International guidelines recommend use of aspirin, beta-blockers, ACE inhibitors and statins in post-MI patients. AIMS: We performed this audit to review the compliance of prescribing practices, in a regional hospital in Ireland, with international guidelines for secondary prevention of coronary artery disease. METHODS: We performed a retrospective case review of 172 patients diagnosed with MI during a 1-year period between January and December 2007. RESULTS: A total of 134 patients fulfilled the inclusion criteria. On discharge, aspirin was prescribed to 131 (97.76%) patients, clopidogrel to 126 (94%), beta-blockers to 117 (87%), ACE inhibitor to 87 (65%), ARB to 10 (7%) and statins to 116 (87%). CONCLUSION: Our audit shows that targets for prescription of secondary prevention medications were not met in a small but significant proportion of patients and calls for review of discharge practices and education to improve compliance with guidelines.
Language:
eng
MeSH:
Adrenergic beta-Antagonists/administration & dosage; Angiotensin-Converting Enzyme Inhibitors/administration & dosage; Coronary Artery Disease/drug therapy/*prevention & control; Guideline Adherence/*statistics & numerical data; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage; Medical Audit; Physician's Practice Patterns/*statistics & numerical data; *Practice Guidelines as Topic; Retrospective Studies; Secondary Prevention
ISSN:
1863-4362 (Electronic); 0021-1265 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorSyed, I A Aen_GB
dc.contributor.authorRiaz, Aen_GB
dc.contributor.authorRyan, Aen_GB
dc.contributor.authorReilly, M Oen_GB
dc.date.accessioned2012-02-01T10:53:04Z-
dc.date.available2012-02-01T10:53:04Z-
dc.date.issued2012-02-01T10:53:04Z-
dc.identifier.citationIr J Med Sci. 2010 Dec;179(4):535-7. Epub 2010 Jul 31.en_GB
dc.identifier.issn1863-4362 (Electronic)en_GB
dc.identifier.issn0021-1265 (Linking)en_GB
dc.identifier.pmid20676796en_GB
dc.identifier.doi10.1007/s11845-010-0527-xen_GB
dc.identifier.urihttp://hdl.handle.net/10147/207976-
dc.description.abstractBACKGROUND: Secondary prevention pharmacotherapy in post-myocardial infarction (MI) patients reduces the risk of subsequent coronary events and overall mortality. International guidelines recommend use of aspirin, beta-blockers, ACE inhibitors and statins in post-MI patients. AIMS: We performed this audit to review the compliance of prescribing practices, in a regional hospital in Ireland, with international guidelines for secondary prevention of coronary artery disease. METHODS: We performed a retrospective case review of 172 patients diagnosed with MI during a 1-year period between January and December 2007. RESULTS: A total of 134 patients fulfilled the inclusion criteria. On discharge, aspirin was prescribed to 131 (97.76%) patients, clopidogrel to 126 (94%), beta-blockers to 117 (87%), ACE inhibitor to 87 (65%), ARB to 10 (7%) and statins to 116 (87%). CONCLUSION: Our audit shows that targets for prescription of secondary prevention medications were not met in a small but significant proportion of patients and calls for review of discharge practices and education to improve compliance with guidelines.en_GB
dc.language.isoengen_GB
dc.subject.meshAdrenergic beta-Antagonists/administration & dosageen_GB
dc.subject.meshAngiotensin-Converting Enzyme Inhibitors/administration & dosageen_GB
dc.subject.meshCoronary Artery Disease/drug therapy/*prevention & controlen_GB
dc.subject.meshGuideline Adherence/*statistics & numerical dataen_GB
dc.subject.meshHumansen_GB
dc.subject.meshHydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosageen_GB
dc.subject.meshMedical Auditen_GB
dc.subject.meshPhysician's Practice Patterns/*statistics & numerical dataen_GB
dc.subject.mesh*Practice Guidelines as Topicen_GB
dc.subject.meshRetrospective Studiesen_GB
dc.subject.meshSecondary Preventionen_GB
dc.titleSecondary prevention for coronary artery disease: are we following the guidelines?en_GB
dc.contributor.departmentWaterford Regional Hospital, Waterford, Ireland. asimsyed01@hotmail.comen_GB
dc.identifier.journalIrish journal of medical scienceen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.